Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II …

The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein
homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease …

Malaria is a global infectious disease that remains a leading cause of morbidity and mortality
in the develo** world. Multiple environmental and host and parasite factors govern the …

Malaria is one of the most devastating human infectious diseases caused by Plasmodium
spp. parasites. A search for an effective and safe vaccine is the main challenge for its …

Placental accumulation of Plasmodium falciparum infected erythrocytes results in maternal
anemia, low birth weight, and pregnancy loss. The parasite protein VAR2CSA facilitates the …

Plasmodium vivax infection, the predominant cause of malaria in Asia and Latin America,
affects~ 14 million individuals annually, with considerable adverse effects on wellbeing and …

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …

Plasmodium vivax is responsible for most of the malaria infections outside Africa and is
currently the predominant malaria parasite in countries under elimination programs. P. vivax …